CapyFin

Calendar Reports

Search for a symbol...

Loading...

CapyFin Real-time Earnings Reports.

Products

Earnings
API

Get in Touch

Contact Us
X (Twitter)
LinkedIn

Resources

Privacy Policy
Terms of Service
Sign Up
Sign In

© 2026 CapyFin. All rights reserved.

Disclaimer: CapyFin provides financial data and AI analysis for informational purposes only and does not provide investment advice or recommendations. Real-time data and AI outputs may be inaccurate, incomplete, delayed, or contain errors or hallucinations. Investing involves risk, including loss of principal. The service is provided “as is” and we disclaim liability to the fullest extent permitted by law. See our Terms of Service and Privacy Policy.

Amicus Therapeutics - CapyFin

Amicus Therapeutics

FOLD · NASDAQ🇺🇸

Earnings Dividends Seasonality Metrics

Reported earnings 3 months ago

Previous year: $127M

Previous year: $0.06

Total GAAP Operating Expenses

Previous year: $100M

Total Non-GAAP Operating Expenses

Previous year: $82.1M

Total Revenue Growth at CER

Previous year: $113M

Cash and Equivalents

Previous year: $260M

Previous year: $749M

Loading...

Key Statistics

Market Cap

$4.48B

P/E Ratio

-428.18

Sector

N/A

Industry

N/A

52-Week High

$14.3

52-Week Low

$5.63

Total GAAP Operating Expenses

$149M

Total Non-GAAP Operating Expenses

$128M

Total Revenue Growth at CER

18%

Galafold Revenue Growth at CER

12%

Pombiliti + Opfolda Revenue Growth at CER

58%

Amicus Therapeutics

Unlock previous datapoints

Amicus Therapeutics

Unlock previous datapoints

Amicus Therapeutics Revenue by Segment

Revenue by Segment

Galafold Revenue

Unlock previous datapoints

CapyFin.com

Pombiliti + Opfolda Revenue

CapyFin.com

Revenue & Expenses

Visualization of income flow from segment revenue to net income

Historical Earnings Impact

Analyze how earnings announcements historically affect stock price performance

Avg. Return Before/After Earnings

Loading earnings performance data...

Loading earnings reaction data...